Little is known about hypertension in the HIV-infected population. This study aimed to assess the prevalence of hypertension and related factors in HIVinfected patients.
C
ombination antiretroviral therapy (CART) has resulted in durable suppression of HIV replication, prevention of AIDS-defining opportunistic infections and malignancies, and a substantial impact on survival rate and quality of life in HIV-infected patients. 1 However, the potential for maintaining these patients on treatment for decades may be limited by a variety of metabolic abnormalities observed in patients on CART, including dyslipidemia, fat redistribution, and insulin resistance, 2, 3 particularly when therapy contains protease inhibitors. 4 This fact has raised the concern that the HIVinfected population may be at increased risk for cardiovascular disease in the long term, as has been described in two large prospective studies. 5, 6 The absolute cardiovascular risk in any individual is determined by a complex interplay of several risk factors that include older age, positive family history, smoking, hypertension, elevated blood lipids, and diabetes. 7 In the pre-CART era, elevated blood pressure (BP) was frequently associated with HIV-related complications such as renal failure and vasculopathy. 8 Recent reports raise the suspicion that CART may also induce hypertension. 9 -15 A few comparative studies on BP in HIV-infected patients, mainly those with lipodystrophy or the metabolic syndrome, have been reported. 10, 12, 15 Because the identification and management of cardiovascular risk factors in HIV-infected patients has become a more pressing issue, hypertension must be taken into account in this population. The present study focuses on the prevalence of hypertension and possible related factors in a large group of HIVinfected patients.
Methods

Study Population
A cross-sectional study was conducted in HIV-infected patients managed at the outpatient Infectious Disease Unit of the Hospital del Mar, Barcelona, from January through December 2003 and followed for at least 6 months to complete three visits. A control group to compare hypertension prevalence was recruited at the same time from hospital and university staff, nonretributed blood donors, and subjects who attended the ophthalmology outpatient clinic for visual acuity examination. The protocol study approved by the local Ethics Committee consisted of physical examination. All participants were 20 years of age or older and were evaluated by trained physicians after giving their informed consent. Exclusion criteria for patients included withdrawal of CART and evidence of clinical signs of active AIDS in the 3 months before entry and during the study owing to their possible impact on anthropometric parameters and BP values.
Data Collection
Age, gender, HIV disease stage according to the 1993 Centers for Disease Control and Prevention (CDC) classification of HIV disease, 16 HIV exposure (mutually exclusive in the following order: intravenous drug use, male homosexual activity, heterosexual activity), and type and duration of CART were recorded. Lipodystrophy was defined and categorized by the blinded physician (HK)-assessed presence of peripheral lipoatrophy (face, arms, legs, buttocks, and prominent veins), central lipohypertrophy (abdomen, breasts, dorsocervical region), and mixed lipodystrophy. Weight and height were measured by standard methods. After the participant had rested seated for 10 min in a quiet room, BP was measured in the left arm with the elbow flexed at heart level by the same physician (CJ) using a 1042 Riester sphygmomanometer (Jungingen, Germany), with diastolic pressures at Korotkoff phase 5 (disappearance of sounds). Three readings were obtained, and the average of the second and third systolic and diastolic BP readings was used in the analyses. Patients and controls were seen at least three times during the 6-month follow-up period.
Hypertension diagnosis was defined when the two readings obtained at the three consecutive visits were Ն140 or 90 mm Hg, or current use of antihypertensive therapy. Pulse pressure was calculated as systolic minus diastolic BP. Creatinine clearance was estimated by the method of Cockcroft and Gault. 17 
Statistical Analysis
Student t test was performed to assess differences between the two means. When data were not normally distributed, Mann-Whitney U test was used. Either 2 test or Fisher's exact test was used to test the degree of association of categorical variables. Computed factors in the univariate analysis were age, gender, body mass index, HIV transmission group (dichotomized as intravenous drug users versus sexual transmission), HIV clinical stage (dichotomized as asymptomatic, A stage of CDC versus symptomatic, B and C stage of CDC), current and nadir CD4 cell count, plasma HIV RNA categorized as detectable (Ͼ500 copies/mL) or undetectable, lipodystrophy, duration of CART, and type of CART classified as antiretroviral naive, no protease inhibitor exposure, and past or current protease inhibitor exposure.
Variables demonstrating a univariate relationship (P Ͻ .05) with the outcome variable were included in the model to assess the effect of independent variables on hypertension diagnosis. A P value Ͻ .05 was considered statistically significant. Goodness-of-fit was verified with the Hosmer and Lemeshow statistic method. All statistical analyses of database results were performed with the Statistical Package for the Social Sciences (SPSS for Windows, v.11.5, Chicago, IL).
Results
Of the 805 eligible HIV-infected patients, only 710 (88.2%) agreed to participate in the study protocol and completed all visits. Of these, 626 (88.2%) were on CART and 84 (11.8%) naive. Demographic and clinical characteristics of HIV infection are shown in Table 1 . Hypertension was detected in 93 (13.1%) (25 receiving antihypertensive therapy). Eightyeight were on CART and five were naive HIV-infected patients. Among the 802 recruited controls, hypertension was detected in 108 (71 on medication) subjects (13.5%) ( Table 1) . By gender, the prevalence of hypertension in HIV-infected patients was 15.5% in men and 7% in women and 14.6% and 8.8%, respectively, in the control group.
As shown in Table 2 , hypertensive HIV-infected patients presented with older age, male predominance, higher body mass index, and pulse pressure compared with normotensive HIV-infected patients. Among the characteristics of HIV disease only the transmission group category significantly differed between hypertensive and normotensive HIV-infected patients. Lipodystrophy was more common among hypertensive patients compared with normotensives (53.8% v 34.0%, P ϭ .0001). Moreover, CART, particularly protease inhibitor exposure, was significantly associated with hypertension. 
Discussion
Blood pressure is considered an important modifiable risk factor in both primary and secondary cardiovascular prevention, and this is reflected in current clinical statements for the general population, 7 as well as in HIV-infected subjects. 18 Using Joint National Committee-Sixth Report (JNC-VI) criteria, 19 13.1% of HIV-infected patients and 13.5% of the control group were estimated to have hypertension. This estimate is globally lower than that reported in epidemiologic studies for the general population in European countries. 20 However, when comparing the age-specific prevalence of epidemiologic hypertension diagnosis, the prevalence among participants aged 35 through 44 years was nearly similar in the present study to that of the European population. 20 We wish to emphasize that 26.9% of HIV-infected subjects with hypertension were detected by the criterion of antihypertensive drug therapy use versus 65.7% of controls. This could indicate that, if recruitment bias was assumed to be improbable, HIV-infected patients were less likely to be treated for hypertension, as the hypertension prevalence was similiar in both groups.
Although BP levels are usually categorized in cardiovascular risk studies in the HIV-infected population, 5, 21, 22 hypertension prevalence as the main study objective has received little attention and data are controversial or vary widely. Potential explanations for these dissimilar results include differences in study design, methodologic aspects, cut-off values for BP, and differences in the patient populations studied.
10,12,15 Our hypertension prevalence was higher than that reported for HIV-infected men of the Aproco cohort, 23 lower than the Italian cohort, 12 and similar to Norwegian cohort. 15 Some aspects of the present study need to be highlighted. First, concerning BP measurement, and according to the American Heart Association, BP was measured with the patient's elbow flexed at heart level. 24 From a clinical viewpoint, this apparently insignificant fact has important implications. In this regard, Hemingway et al 25 found BP readings to be higher when the arm was parallel to the torso and would decrease by 8.8 to 14.4 mm Hg with the arm raised to a perpendicular position. Second, all HIVinfected patients had at least a 6-month follow-up with three visits to support the diagnosis of hypertension and thus avoid hypertension overdiagnosis. In this respect, the initial diagnosis of hypertension could not be clinically confirmed in 47.5% of patients during follow-up. Third, abnormal fat redistribution was more frequently observed in hypertensive HIV-infected patients and, in regression analysis, the presence of a lipoaccumulation pattern of fat IQR ϭ median interquartile range; NS ϭ not significant. * Number of subjects (%) diagnosed of hypertension by the criterion of antihypertensive therapy use. † HIV clinical categories: A (asymptomatic, acute HIV, or persistent generalized lymphadenopathy), B (symptomatic, not categories A or C), and C (AIDS-indicator conditions). 16 redistribution, which includes lipohypertrophy plus mixed forms of lipodystrophy, increased the odds ratio of elevated BP twofold. The link between lipodystrophy and hypertension is not surprising because fat redistribution, hyperlipidemia, insulin resistance, and hyperglycemia have been extensively reported in HIV-infected subjects OR ϭ odds ratio; CI ϭ confidence interval; CART ϭ combination antiretroviral therapy.
The goodness-of-fit was verified with the Hosmer and Lemeshow statistical method (P ϭ .5). * Lipoaccumulation pattern includes lipohypertrophy plus mixed forms.
treated with protease inhibitors. 3, 26 Although protease inhibitor therapy was not an independent factor in the logistic regression model, when lipodystrophy was not taken into account in this model, exposure to protease inhibitors emerged as significantly and independently associated with hypertension. Thus, the influence of protease inhibitor therapy on BP levels could, at least in part, be mediated through the development of lipodystrophy.
Limitations of the present study are mainly related to the observational design and cross-sectional nature of the current analyses. The results reported herein are only associations from which no conclusions regarding causality can be drawn. Although sociodemographic characteristics of the clinical population studied, such as the high prevalence of current smokers, intravenous drug users, and male predominance, are quite similar to those of the Spanish HIV population in accordance with the National AIDS Registry, 27 data on prevalence results could be generalized with caution to the global HIV population. On the other hand, information on other environmental factors such as physical activity or diet and salt intake was not collected.
The present results suggest no meaningful difference in prevalence of hypertension between subjects with and without HIV infection. Considering that the substantial benefits of CART clearly outweigh the possible complications associated with this therapy, we conclude that the influence of CART appears to have little impact on the prevalence of hypertension. However, it must be borne in mind that with progressive aging of the HIV-infected population and the expected long-term use of CART, the need will arise to prevent an increased incidence in elevated BP in this population, particularly those with lipoaccumulation.
